7-5/2013/EU/WC-0034 Government of India Directorate General of Health Services Central Drugs Standard Control Organisation (International Cell)

FDA Bhawan, Kotla Road, New Delhi-110002 Dated

1 5 JUN 2022

To

M/s. Dr. Reddy's Laboratories Ltd. Chemical Technical Operations - Unit II Plot Nos. 1, 75A, 75B, 105, 110, 111 & 112 Sri Venkateswara Co-operative Industrial Estate, Bollaram (V) Jinnaram (M), Sangareddy (Dist.), Telangana, India

SUB:- Written Confirmation of M/s. Dr. Reddy's Laboratories Ltd., Chemical Technical Operations - Unit II, Plot Nos. 1, 75A, 75B, 105, 110, 111 & 112, Sri Venkateswara Cooperative Industrial Estate, Bollaram (V), Jinnaram (M), Sangareddy (Dist.), Telangana, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your application submitted to CDSCO, Hyderabad Zone office, and the recommendation received from DDC (I), Hyderabad Zone on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

- 1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
- 2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
- 3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
- 4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.



- 5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.
- 6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.
- 7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
- 8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
1	16	5 JUN 2022	16.06.2025
Amended	10	J JOH ZULE	10.00.2023

Yours faithfully,

(Dr. V. G. Somani)

Drugs Controller General (India)



GOVERNMENT OF INDIA MINISTRY OF HEALTH & FAMILY WELFARE Central Drugs Standard Control Organization

CERTIFICATE NO. :

WC-0034

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site:

M/s. Dr. Reddy's Laboratories Ltd.

Chemical Technical Operations – Unit II Plot Nos. 1, 75A, 75B, 105, 110, 111 & 112

Sri Venkateswara Co-operative Industrial Estate Bollaram (V), Jinnaram (M), Sangareddy (Dist.)

Telangana, India

List of APIs:

010

Sr. No.	Active substance (s)	Activity(ies)
1.	Atorvastatin Calcium Trihydrate IH/Ph. Eur	Manufacturing & Packing
2.	Atorvastatin Calcium IH/USP	Manufacturing & Packing
3.	Ciprofloxacin Ph. Eur/USP	Manufacturing & Packing
4.	Ciprofloxacin Hydrochloride Ph. Eur/USP	Manufacturing & Packing
5.	Dutasteride IH	Manufacturing & Packing
6.	Finasteride Ph. Eur/USP-	Manufacturing & Packing
7	Fondaparinux Sodium IH	Manufacturing & Packing
8.	Glimepiride USP/Ph. Eur	Manufacturing & Packing
9.	Ketorolac Trometamol Ph. Eur	Manufacturing & Packing
10,	Levofloxacin Hemihydrate IH/Ph. Eur	Manufacturing & Packing
11.	Levofloxacin USP	Manufacturing & Packing
12	Moxifloxacin Hydrochloride USP/Ph. Eur	Manufacturing & Packing
13.	Raloxifene Hydrochloride USP/Ph. Eur	Manufacturing & Packing
14.	Repaglinide USP/Ph. Eur	Manufacturing & Packing
15.	Rizatriptan Benzoate USP/Ph. Eur	Manufacturing & Packing
16.	Telmisartan USP/Ph. Eur	Manufacturing & Packing

ITEM(S) SIXTEEN (16) ONLY

The Written Confirmation remains valid until: 16.06.2025

Signature

1 5 JUN 2022

Stamp of